The University of Southampton
University of Southampton Institutional Repository

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Treatment with bevacizumab plus IFN and sunitinib has clinically relevant and statistically significant advantages over treatment with IFN alone in patients with metastatic RCC. In people with three of six risk factors for poor prognosis, temsirolimus had clinically relevant advantages over treatment with IFN, and sorafenib tosylate was superior to best supportive care as second-line therapy. The frequency of adverse events associated with bevacizumab plus IFN, sunitinib and temsirolimus was comparable with that seen with IFN, although the adverse event profile is different. Treatment with sorafenib was associated with a significantly increased frequency of hypertension and hand-foot syndrome. Estimates from the PenTAG model suggested that none of the interventions would be considered cost-effective at a willingness-to-pay threshold of 30,000 pounds per QALY
1366-5278
1-184
Thompson Coon, J.
361482fe-af95-4c17-a1fa-0fe49af0d237
Hoyle, M.
af04245a-4935-4c89-93d0-2aefaad30ed2
Green, C.
a4440ea4-08aa-4bde-810e-9b615150e39e
Liu, Z.
f2d813f1-8806-4fd5-a719-2e9357f2453f
Welch, K.
2603c214-aace-486f-8723-b006873248a5
Moxham, T.
a98c30c4-b839-4028-9539-b9367d8f9dc0
Stein, K.
5f0b93b6-a47b-4976-b813-f498931d5286
Thompson Coon, J.
361482fe-af95-4c17-a1fa-0fe49af0d237
Hoyle, M.
af04245a-4935-4c89-93d0-2aefaad30ed2
Green, C.
a4440ea4-08aa-4bde-810e-9b615150e39e
Liu, Z.
f2d813f1-8806-4fd5-a719-2e9357f2453f
Welch, K.
2603c214-aace-486f-8723-b006873248a5
Moxham, T.
a98c30c4-b839-4028-9539-b9367d8f9dc0
Stein, K.
5f0b93b6-a47b-4976-b813-f498931d5286

Thompson Coon, J., Hoyle, M., Green, C., Liu, Z., Welch, K., Moxham, T. and Stein, K. (2010) Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technology Assessment, 14 (2), 1-184. (doi:10.3310/hta14020). (PMID:20028613)

Record type: Article

Abstract

Treatment with bevacizumab plus IFN and sunitinib has clinically relevant and statistically significant advantages over treatment with IFN alone in patients with metastatic RCC. In people with three of six risk factors for poor prognosis, temsirolimus had clinically relevant advantages over treatment with IFN, and sorafenib tosylate was superior to best supportive care as second-line therapy. The frequency of adverse events associated with bevacizumab plus IFN, sunitinib and temsirolimus was comparable with that seen with IFN, although the adverse event profile is different. Treatment with sorafenib was associated with a significantly increased frequency of hypertension and hand-foot syndrome. Estimates from the PenTAG model suggested that none of the interventions would be considered cost-effective at a willingness-to-pay threshold of 30,000 pounds per QALY

Full text not available from this repository.

More information

Published date: January 2010
Organisations: Faculty of Medicine

Identifiers

Local EPrints ID: 351812
URI: http://eprints.soton.ac.uk/id/eprint/351812
ISSN: 1366-5278
PURE UUID: 9cc9cb83-a0a3-487d-a92d-4737912551b0

Catalogue record

Date deposited: 25 Apr 2013 11:05
Last modified: 16 Jul 2019 21:35

Export record

Altmetrics

Contributors

Author: J. Thompson Coon
Author: M. Hoyle
Author: C. Green
Author: Z. Liu
Author: K. Welch
Author: T. Moxham
Author: K. Stein

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×